Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS
1 vistas
• 07/16/23
0
0
Empotrar
administrator
Suscriptores
Visit http://www.ecancer.org for more
Prof Margolese (The Jewish General Hospital, McGill University, Montreal, Canada) talks to ecancertv at ASCO 2015 about a federally funded phase III trial that suggests postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios